OneAlphaMed connected specialized biologic distribution directly with a telehealth support ecosystem — ensuring that not a single patient missed a dose due to supply chain, access, or adherence barriers.
Industry / Specialty
Pharmaceutical & Healthcare
Scale / Audience
15,000+ HCPs
Core Solutions
Co-created Certification
Time to Value
Pan-India Deployment
Stop funding clicks. Start building undisputed credibility for your brand today.
Specialty biologic therapies for autoimmune conditions represent some of the most clinically impactful — and operationally fragile — pharmaceutical products on the market. For 3,200+ patients across 9 states managing complex autoimmune conditions, the gap between a prescription being written and a patient reliably receiving and correctly self-administering their biologic was filled with friction: specialty pharmacy delays, cold-chain logistics failures, needle-phobia-driven missed injections, and inadequate adherence support from overstretched clinical teams. OneAlphaMed designed and deployed an integrated solution connecting specialized biologic distribution infrastructure directly with a dedicated telehealth nurse support ecosystem — creating a seamless, monitored patient journey from prescription to administration that achieved zero supply chain gaps across the program’s first operational year.
Getting a specialty biologic from a manufacturer to a correctly-administered patient dose is one of the most operationally complex processes in healthcare — and failure at any single step has direct clinical consequences.
Specialty biologic prescriptions routinely navigated a multi-step fulfillment process — prior authorization, specialty pharmacy routing, cold-chain shipment, and patient delivery — that averaged 17 days from prescription to first dose in the program's baseline assessment. This 17-day gap was causing measurable disease activity increases in newly prescribed patients, with 23% experiencing a clinical setback during the access delay period that required additional medical intervention.
A significant proportion of biologic shipments to patients' home addresses were experiencing cold-chain integrity failures — driven by unpredictable delivery timing, patients who were not home to receive temperature-sensitive shipments, and inadequate patient education about storage requirements. The resulting product wastage rate was both clinically concerning (patients receiving potentially compromised medication) and economically significant (specialty biologic unit costs make wastage a substantial direct cost).
Even when patients successfully received their biologic, the self-injection adherence rate at 6 months was below 65% — driven by needle phobia, injection site anxiety, dose timing confusion, and the absence of any structured patient support beyond the specialty pharmacy's standard medication guide insert. Low adherence directly undermined clinical outcomes and generated the perception that the therapy was ineffective, driving unnecessary therapeutic switches.
OneAlphaMed designed an end-to-end integration between specialized biologic distribution infrastructure and a proactive telehealth support team — closing every gap in the patient journey from prescription to reliable administration.
OneAlphaMed partnered with a specialized biologic-focused pharmacy network and implemented a digitally-integrated prior authorization processing system that reduced the prescription-to-dispensing timeline from 17 days to an average of 6 days. The PA processing system included automated payer-specific form generation, real-time PA status tracking for both the prescribing physician and the patient, and a dedicated PA appeal team for initial denials.
OneAlphaMed implemented a patient-synchronized delivery scheduling system — contacting patients 48 hours before each shipment to confirm delivery availability, offering flexible delivery window selection and secure access box options for patients in apartment buildings, and providing real-time shipment temperature tracking accessible to both the patient and the telehealth nursing team. A dedicated cold-chain exception protocol triggered an immediate replacement shipment within 24 hours of any temperature excursion alert.
A dedicated team of immunology-trained telehealth nurses provided structured, protocol-driven support across the patient's first 12 months of biologic therapy — including a pre-first-injection coaching call, injection technique video review, dose timing reminders synchronized with the patient's schedule, and proactive monthly adherence check-ins that identified emerging adherence barriers before they resulted in missed doses.
The Zero-Gap Patient Journey.
The innovation was systemic rather than technological — recognizing that specialty biologic patient support programs fail not because any individual component is poorly designed, but because the components operate in isolation. By integrating supply chain, delivery logistics, and clinical adherence support into a single, monitored patient journey — with a dedicated human team accountable for zero gaps at every transition — OneAlphaMed created a care model where the complexity of specialty biologic access became invisible to the patient.
The integrated program delivered zero-gap supply chain performance alongside dramatic improvements in adherence and clinical outcomes.
The integrated ecosystem delivered measurable improvements in every dimension of the specialty biologic patient experience — from first prescription to long-term therapy maintenance.
Experienced the transformative difference between navigating a fragmented specialty biologic access system alone and being guided through a seamless, monitored patient journey by a dedicated clinical support team. The program's 12-month adherence rate of 89% — compared to a 65% baseline — translated directly into measurably improved disease activity scores and significantly reduced emergency clinical interventions among the program population.
Gained complete visibility into their patient's supply chain and adherence status through an integrated prescriber dashboard — eliminating the uncertainty of not knowing whether a prescribed therapy was actually being taken, and receiving proactive alerts when a patient's adherence pattern warranted clinical attention. Physician satisfaction with the program was cited as a key driver of sustained program participation and high new-patient enrollment rates.
Demonstrated that specialty biologic patient support programs can be a measurable source of competitive advantage — with physicians who actively managed patients through the program showing significantly higher brand preference and new patient enrollment rates than those without access to the integrated support ecosystem. The program's documented 89% adherence rate became a key clinical outcome data point in market access and formulary discussions.
OneAlphaMed operates a pharmacy network management layer that interfaces with the primary specialty pharmacy partners in each state — managing the prescription routing, PA processing, and delivery scheduling through a single integrated digital platform regardless of which specific pharmacy entity fulfills the prescription in a given state. This abstraction layer means that neither the patient nor the prescribing physician needs to navigate state-specific pharmacy network differences; the complexity is entirely absorbed in our operational infrastructure.
For patients in locations where standard courier delivery cannot guarantee the required temperature window, OneAlphaMed implements alternative delivery protocols including: scheduled delivery via specialized medical courier services with active refrigeration; pharmacy pickup with ice pack packaging for self-transport; and, in extreme cases, coordination with local healthcare facility cold-chain storage for patient collection. Each patient's delivery protocol is individually assessed at enrollment and updated if their circumstances change.
Needle phobia management is embedded as a specific protocol stream within the telehealth nursing program. Patients who self-identify as needle-phobic at enrollment receive a dedicated pre-injection anxiety management coaching session, access to an auto-injector device trainer, and a specially designed gradual desensitization injection confidence-building sequence managed by the telehealth nurse over the first three weeks of therapy. In cases of persistent severe needle phobia, the telehealth nurse coordinates a referral for psychological support through the patient's existing care team.
+91 9811660635
info@onealphamed.com
2414, Ground Floor, Aravali Vihar, Sector 49 Faridabad, Haryana – 121001 India
Copyright © 2026 OneAlphaMed. All Rights Reserved.